Home
FHI Clinical

FHI Clinical Market Share Analysis for June 2026

Every day, our community of professionals is involved in mission-driven research around the globe, developing solutions to manage complex research in

Industry: N/A

Domainfhiclinical.com

Year Founded2019

Employees51 - 200

Annual Revenue--

FHI Clinical

FHI Clinical (including company regionals)

fhiclinical.com

See more website traffic and engagement information

Total visits to FHI Clinical's top domains

Understand FHI Clinical market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

fhiclinical.com--

See more with Sales Intelligence

Avg. visit duration in FHI Clinical's top domains

Analyze FHI Clinical engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

fhiclinical.com--

See more with Sales Intelligence

Avg. pageviews on FHI Clinical's top domains

See how FHI Clinical keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

fhiclinical.com--

See more with Sales Intelligence

FHI Clinical top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by FHI Clinical

These are the website technologies, by industry, used by FHI Clinical top domains

Payment & Currencies (5)

Visa

Advertising (4)

DoubleClick

Widget (4)

Twemoji

Content Management System (3)

WordPress

More Technologies

11

See all

News & Signals from FHI Clinical

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsFHI Clinical Inc. acquires Tcd Global.FHI Clinical announces its intent to acquire TCD Global.

NewsFHI Clinical Inc. hired Evette on Apr 1st '20.Evette joined FHI Clinical in April 2020.

NewsTiziana Life Sciences plc partnered with FHI Clinical Inc. on Jun 23rd '21.Tiziana Life Sciences PLC (NASDAQ: TLSA ) announces that it has endorsed an agreement with FHI Clinical, a worldwide scientific contract research organization, to direct a Phase 2 Proof-of-concept revision in Brazil to assess the security, acceptability, and effectiveness of intranasal Foralumab in hospitalized patients with stark coronavirus illness 2019 (COVID-19) and respiratory irritation.